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Summary We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic
carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated
with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high
SPF (>4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall
(P = 0.004 and P <0.0001) as well as prostate cancer survival (P = 0.002 and P <0.0001). Ten-year overall
survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the
corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven
tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of
those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not
significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free
survival in patients treated hormonally. In conclusion, dletection of high SPF in prostate cancer may indicate
lack of hormonal responsiveness and poor prognosis.
Analysis of tumour DNA ploidy and S-phase fraction (SPF)
by flow cytometry has been shown to provide additional
independent information to prognostic assessment in a varie-
ty of malignancies (Merkel & McGuire, 1990; Hedley, 1989).
Several studies indicate that prostate cancer patients with
DNA-aneuploid tumours have shorter disease-free and
overall survival than those with DNA-diploid tumours (Ford-
ham et al., 1986; Lee et al., 1988; Montgomery et al., 1990;
Nativ et al., 1989; Stephenson et al., 1987; Winkler et al.,
1988). However, it is still controversial whether aneuploidy is
an independent prognostic indicator. At least four groups
have reported DNA aneuploidy to be an additional prognos-
tic factor in prostate cancer (Adolfsson et al., 1990; Mont-
gomery et al., 1990; Nativ et al., 1989; Stephenson et al.,
1987), whereas some other investigators have failed to detect
any independent value for aneuploidy after correcting for the
effect of other prognostic indicators (Detjer et al., 1989;
Haugen & Mjolner6d, 1990; Ritchie et al., 1988).
Few investigators have studied SPF from prostatic car-
cinomas. SPF appears to be higher in carcinomas than in
benign prostate lesions (Schultz et al., 1985) as well as in
poorly differentiated carcinomas as compared to well-
differentiated ones (Neill et al., 1989). SPF has also been
found to be higher in DNA-aneuploid tumours than in DNA
diploid ones (Frankfurt et al., 1984). However, the actual
prognostic value of SPF in prostate cancer has remained
unknown. In the present study we compared the significance
of tumour DNA ploidy and SPF in the assessment of long-
term prognosis and responsiveness to endocrine therapy in 78
primary prostatic carcinoma patients. A new software prog-
ram was used to more accurately analyse SPFs from DNA
histograms obtained from paraffin-embedded tissues (Kal-
lioniemi et al., 1991).
Materials and methods
Patients
The material consisted of 78 previously untreated histo-
logically confirmed primary prostatic carcinomas diagnosed
at the Tampere University Central Hospital during
1977-1979. The patients were staged using the TNM
classification as recommended by UICC (UICC, 1987). The
number of patients classified as T1, T2, T3 and T4 was 14,
16, 20 and 24, respectively. In four cases data on primary
spread was not available. Twenty-six patients had distant
metastases at the time of diagnosis (M1). Radical prostatec-
tomy was done in four cases and four patients received a
radical dose of radiation therapy. Three patients were treated
with estramustine, whereas 60 received only hormonal
therapy as the primary treatment. In the latter group the type
of endocrine therapy was either orchiectomy (48 cases), oest-
rogen therapy (five cases) or orchiectomy with oestrogen
therapy (seven cases). Disease progression was monitored by
experienced urologists. Of the 60 patients who received
endocrine therapy 50 (83%) were bone scanned. Serum levels
of alkaline and acid phosphatases were also regularly
measured in monitoring progression. Size of the prostate was
primarily evaluated by digital examination, but also ultasonic
measurement was sometimes used. Progression was defined
either as (1) the increase of serum tumour marker levels more
than 30% or over the upper reference value if tumour
markers were normal at the time of diagnosis, (2) definite
increase of primary tumour volume, (3) new findings in the
bone scan or unexplained backache, (4) new ureteric obstruc-
tion, (5) new metastases in the lungs or in the urethra.
Tumourpreparation andflow cytometric analysis
Routinely stained slides of each tumour were examined by a
pathologist who selected representative tissue blocks for
DNA flow cytometry. The samples were Tru-Cut- needle
biopsies in 41 cases, transurethral resection specimens in 28
cases and open surgical biopsies in nine cases. In case of
transurethral resection specimens, only tumour-rich areas
were used for flow cytometry. The histological typing and
grading was evaluated by one experienced uropathologist
according to the WHO histopathological grading of prostatic
tumours (Mostofi, 1980). Fifty micrometer sections were cut
from corresponding paraffin-embedded blocks. The sections
were dewaxed using a modification of Hedley's method
(Hedley et al., 1983) as previously described (Kalhoniemi,
1988; Vindelov et al., 1983). Briefly, the sections were washed
twice with xylene and rehydrated in a sequence of 100%,
95%, 70% and 50% ethanol and finally washed twice in
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distilled water. The sections were digested overnight with
trypsin and stained with 50lgmlm' ethidium bromide in a
hypotonic detergent solution followed by RNAase treatment.
The nuclear suspensions were filtered through nylon net
(pore size 55gm) and analysed with an EPICS C flow
cytometer (Coulter Electronics Inc, Hialeah, FL) using
488 nm argon laser excitation. At least 10,000 nuclei from
each specimen were scanned at a rate of 40-200 nuclei/s.
Analysis and interpretation ofDNA histograms
DNA aneuploidy was considered to be present if two clearly
separate peaks were found in the DNA histogram. The
coefficient of variation (CV) of the GO/GI peaks was
8.19 ± 2.05% (mean ± s.d.). The peak with the lowest mean
channel number was defined as the DNA-diploid peak and
was used as a reference in the calculation of DNA index. The
definition of DNA aneuploidy in the tetraploid region (DNA
index 1.80-2.20) was based on the presence of either (1)
more than 15% cells in the tetraploid region of a DNA
histogram with a diploid SPF less than 15% or (2) evidence
of a proliferating tetraploid clone with G2/M-cells and/or
S-phase cells in the octaploid/hypo-octaploid region of a
DNA histogram. The latter criterion was not used if there
was evidence of nuclear aggregation as indicated by the
presence of a peak in the hexaploid region. We have chosen
15% as a cut-off limit since this limit has been systematically
used in our laboratory for the analysis of other human
malignancies. Our experience indicates that if cell cycle
distributions are calculated from cell populations (like small
tetraploid peaks) accounting for less than 15% of the total
cell count, the interference by nuclear debris and aggregates
makes the analysis very unreliable.
Cell cycle distribution was analysed using the Multicycle
software program (Phoenix Flow Systems, San Diego, CA).
Most of the paraffin-embedded tumours produced a DNA
histogram with a predominantly flat debris distribution on
the left side of the diploid GO/GI peak. This debris is mostly
caused by cleaved nuclei that are produced during specimen
preparation (Kallioniemi et al., 1991). The MultiCycle soft-
ware models the background debris by assuming a random
probability of any nucleus being cut into random-sized
fragments during sample processing. The background signals
are then numerically eliminated from the DNA histogram on
a channel-by-channel basis. Any residual excess background
at low histogram channels is fitted by a power function. After
debris subtraction a zero-order Dean and Jett (Dean & Jett,
1974) model for cell cycle analysis was used. In aneuploid
cases only the cell cycle of the aneuploid clone was registered.
Interference caused by the S- and G2/M-phase cells of the
diploid clone was accounted for either by modelling two
proliferating cell cycles or by excluding the G2/M peak of the
diploid clone from the analysis using a specific software
option. SPF was considered inevaluable in four cases.
Statistical analysis
Statistical analyses of the clinicopathological and survival
data were done using the BMDP Statistical Software Package
(Dixon, 1981). The significance of survival differences
between patient groups was evaluated using the Mantel-Cox
test (BMDP1L). Clinicopathological correlations of DNA
ploidy were analysed with the Pearson chi-square test
(BMDP4F) and those of SPF by variance analysis
(BMDP7D). For calculating relative risks a univariate Cox
proportional hazard model (BMDP2L) was used.
Results
Thirty-one (40%) of the 78 primary prostatic carcinomas
were DNA-aneuploid. Of the 31 aneuploid cases 16 had a
tetraploid DNA index (1.80-2.20). DNA aneuploidy was
significantly associated with high tumour grade, large size of
prostate and the presence of distant metastases (MI) at the
time of diagnosis (Table I). The incidence of aneuploidy also
tended to be higher in locally advanced tumours (stages
T3-T4) and in tumours from older patients, but these trends
did not reach statistical significance.
Median SPF of all 74 evaluable tumours was 4.2% with a
mean of 6.4 ± 5.8% (± s.d.). DNA-aneuploid tumours had a
higher SPF value (10.7 ± 7.2%) than DNA-diploid ones
(3.9 ± 2.7%). High SPF was associated with poorly differ-
entiated high-grade tumours, large size of prostate, locally
advanced tumours (T3-T4) and the presence of distant
metastases (MI) (Table I). There was also a trend for SPF to
be higher in tumours from older patients.
Progression-free survival rate was shorter in patients with
DNA-aneuploid tumours in comparison to those with DNA-
diploid ones (Figure la). The same difference was observed in
overall survival rates (Figure lb). After correcting for inter-
current deaths the significance of this difference increased
further (Figure 1c). The relative risk of tumour progression
or patient death was about two times higher in DNA-aneuploid
than in DNA-diploid cases. Patients with tetraploid tumours
(DNA index 1.80-2.20) did not have significantly different
survival as those with other types of aneuploidy.
SPF turned out to be a better prognostic factor than DNA
ploidy. Using the median SPF (4.2%) as a cut-off value,
prostate cancer patients with high SPF had a significantly
shorter progression-free survival (Figure 2a), overall survival
(Figure 2b) and survival corrected for intercurrent deaths
(Figure 2c) as those with a low SPF. Ten-year survival rate
corrected for intercurrent deaths in cases with below median
SPF was 80% as compared with 11% in those with above
median SPF. According to a univariate Cox regression
analysis this difference was equivalent to a risk ratio ofabout
7.5. Overall survival rates of patients with below and above
median SPF were 45% and 0%, respectively.
To further evaluate the prognostic value of SPF a stratified
analysis was carried out using survival corrected for intercur-
rent deaths as the end-point (Table II). SPF had a higher
prognostic impact in DNA-diploid than in DNA-aneuploid
cases. Patients with distant metastases (Ml) could not be
subdivided according to SPF into different prognostic
categories, whereas in cases without distant metastases at the
time of diagnoses (MO) SPF was a strong prognostic factor.
An association between high SPF and poor prognosis was
also detected among the well (grade I) and moderately (grade
II) differentiated tumours. SPF did not have additional prog-
nostic value in grade III tumours as virtually all these cases
had a high SPF value.
Table I Clinicopathological characteristics in prostatic carcinoma.
Relation to DNA ploidy and SPF
Aneuploid Aneuploid SPF
Characteristic (No./total) (%) (mean ± s.d.)
Grade I 9/37C 24 4.1 ± 3.4b
Grade II 11/28 39 6.1±4.4
Grade III 11/13 85 13.6± 8.5
Ti 3/14 21 4.1 ±40b
T2 4/16 25 3.7 ± 2.5
T3 7/20 35 6.0 ± 4.9
T4 14/24 58 9.6±7.3
MO 14/52b 27 4.4 ± 3.7b
Ml 13/22 59 9.7±7.0
Clinical size of prostate:
1 I/loa 10 3.6 ± 2.5a
2 14/37 38 5.1±4.1
3 12/24 50 9.1±7.7
4 3/3 100 13.3±6.6
Age of patient:
<65 5/16 31 3.8±3.0
65-75 13/36 36 6.1 ± 5.0
>75 13/26 50 8.3± 7.5
Statistical significance of association: ap<o.05, bp <0.01,
CP<0.001.580 T. VISAKORPI et al.
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Table II The significance of SPF as a predictor of prostatic
carcinoma survival in subgroups of patients defined by other
prognostic indicators
10-year survival
rate (%) P-value
Characteristic n Low SPF High SPF (Mantel-Cox)
All patients 74 80 10 0.0000
DNA diploid 47 80 20 0.0017
DNA aneuploid 27 50 0 0.0395
Grade I 35 100 60 0.0031
Grade II 27 60 10 0.0248
Grade III 12 0 0 0.7226
MO 49 80 40 0.0118
Ml 22 0 0 0.5152
A single SPF cut-off value was used to divide the patients in two
groups. In DNA-diploid and aneuploid cases the cut-off values for
SPF were the means of each group (3.9% and 10.7%, respectively).
All the other comparisons were done using the median 4.2% SPF
value.
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Figure 1 Prognosis of patients with primary prostatic carcinoma
(n = 78) according to the DNA ploidy of the tumour cells. a,
progression-free survival; b, overall survival; c, survival corrected
for intercurrent deaths. RR = relative risk.
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Figure 2 Prognosis of patients with primary prostatic carcinoma
(n = 73) according to the SPF of the tumour cells. A single
cut-off value (4.2%) was used to divide the patients in two groups
of equal size. a, progression-free survival; b, overall survival; c,
survival corrected for intercurrent deaths. RR = relative risk.
Endocrine responsiveness could be monitored in all the 60
patients who were given endocrine therapy as the only
primary treatment. There was no significant difference in the
hormonal response rates between DNA-diploid and DNA-
aneuploid cases (Table III). Neither did the grade of the
tumour show a significant correlation with response rates.
However, SPF levels correlated significantly with endocrine
responsiveness. All seven patients with an SPF value higher
than 12% did not show any measurable response to endo-
crine therapy (Table III), whereas over half of the patients
with lower SPF values responded. If the median value (4.2%)
was used as a cut-off for SPF the relation to endocrine
response was less significant. However, even when using this
cut-offvalue progression-free survival was significantly longer
in hormonally treated patients with low as compared to high
tumour SPF (P = 0.0006, 5.2-fold higher risk of death). If
the tumour SPF was over 12% the median progression-free
interval of patients under hormonal therapy was only 18
months.
Discussion
High tumour proliferation rate as defined by flow cytometric
SPF analysis was shown to predict poor response rate to
endocrine manipulation, rapid disease progression and high
mortality rate in primary prostate cancer. As compared to
Table III The response of prostatic carcinoma to primary hormonal
therapy according to DNA ploidy, SPF, grade, primary extension
(T) and metastasis (M) of the tumours
Progression or Partial or
stable disease complete remission
Characteristic No. Percent No. Percent
All patients 33 55 27 45
DNA diploid 21 57 16 43
DNA aneuploid 12 52 11 48
Low SPF (< 12%)a 25 49 26 51
High SPF (>12%) 7 100 0 0
Grade I 14 58 10 42
Grade II 12 48 13 52
Grade III 7 64 4 36
T1 and 2 10 55 8 45
T3 11 58 8 42
T4 11 52 10 48
MO 20 54 17 46
M1 12 55 10 45
aPearson chi-square P=0.0110.
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DNA ploidy, which also previously has been found to predict
disease outcome (Fordham et al., 1986; Haugen &
Mjolnerod, 1990; Lee et al., 1988; Montgomery et al., 1990;
Nativ et al., 1989; Stephenson et al., 1987; Winkler et al.,
1988), SPF had a stronger impact and provided additional
information on prognosis both among the DNA-diploid and
DNA-aneuploid groups. Previously, only two small studies
have been published on SPF analysis by flow cytometry in
prostate cancer (Neill et al., 1989; Frankfurt et al., 1984).
These publications did not include follow-up studies. They
reported a correlation between SPF and DNA ploidy as well
as between SPF and tumour grade, which we also were able
to confirm in the present larger series.
Insensitivity to primary endocrine therapy was character-
istic to a small subgroup of cases with very high (> 12%)
SPF levels. No other tumour parameter including ploidy,
grade or stage correlated significantly with the degree of hor-
monal response. It is generally recognised that the prediction
of responsiveness to endocrine therapy is difficult in prostate
cancer (Schultze & Isaacs, 1986). On the basis of in vitro
studies of prostate cancer cell lines it appears that a major
factor contributing to endocrine responsiveness is the
presence on a functional androgen receptor (Horoszewicz et
al., 1983). Although androgen receptor negative tumour cells
have been described by immunocytochemistry (Demura et
al., 1988), there is no direct evidence of a correlation between
steroid receptor status of prostate tumours and clinical re-
sponse rates. It remains to be determined, whether the
absence of a measurable hormonal response in the rapidly
proliferating tumours is specifically due to the lack of
androgen-mediated growth regulation and/or activation of
alternative growth promoting mechanisms (Morris & Dodd,
1990). Tumour grade did not predict endocrine responsive-
ness suggesting that the effect of SPF was probably not
related to the loss of differentiation of tumour cells. It should
be emphasised that a number of prostatic carcinomas with
low SPF also responded poorly or not at all to hormonal
manipulation. Thus, tumour proliferation rate alone may not
be a sufficient marker ofendocrine responsiveness in prostate
cancer but should be taken into account as a potential
confounding variable in prospective trials on endocrine
therapy.
High SPF had the strongest impact on prostate cancer
survival among patients who did not have distant metastases
at the time ofdiagnosis (MO-stage). Our patient material was
still too small to definitely subdivide the MO cases further
according to T-stage and define the prognostic impact of SPF
in such subgroups. However, preliminary data would indicate
that SPF is a prognostic parameter in both early (TI-T2)
and more advanced (T3-T4) non-metastatic tumours. Taken
alone, SPF is about as powerful prognostic indicator than
M-stage, T-stage or grade and appears to correlate even
better with therapy response. However, SPF is significantly
associated not only with the T- and M-stage, but also with
grade and tumour ploidy, all established prognostic factors in
prostate cancer. To better evaluate the exact value of SPF in
determining prognosis and for guiding clinical treatment
decisions in each prostate cancer subgroup we are currently
evaluating a larger patient material. This would make it
possible to perform multivariate regression analyses and to
develop regression trees for guiding prognostic assessments.
Analysis of SPF by flow cytometry from tumours in
general, and from paraffin-embedded material in particular,
has been criticised due to lack of accuracy and repro-
ducibility (Vindelov & Christensen, 1990). However, DNA
flow cytometry remains the best method available to access
archival material and determine proliferation status of
tumours from patients followed clinically for many years
(Hedley, 1989). Futhermore, recent progress in the develop-
ment of sophisticated computer models has made it possible
to overcome some of the shortcomings in the methodology.
It is nowadays possible to effectively discriminate the aneu-
ploid SPF from overlapping diploid cell cycle as well as
compensate for nuclear debris overlying the SPF in DNA
histograms. We have recently demonstrated that the prognos-
tic value of SPF is improved by subtracting the debris signals
using a 'sliced nuclei' model that effectively eliminates most
of the debris from archival tumour tissues underlying in
DNA histograms (Kallioniemi et al., 1991). We could repro-
ducibly analyse cell cycle distributions from as many as 95%
ofthe DNA histograms considered evaluable for DNA ploidy,
which makes it unlikely that a selection bias could have
affected our comparison of SPF and DNA ploidy as prog-
nostic indicators (Hedley et al., 1987).
However, it should be recognised that in DNA-diploid
tumours it is still not possible to discriminate the cell cycle of
tumour cells from that of stromal and inflammatory cells
that are projected on the same channels in the DNA histo-
gram. In the present study we tried to prepare tumour-rich
areas from paraffin blocks for flow cytometric analysis. Since
SPF values had better prognostic value in the DNA-diploid
than in the DNA-aneuploid cases it is likely that at least the
presence of an elevated SPF value in DNA-diploid tumours
should be taken into account. Furthermore a correlation has
been reported between flow cytometric SPF and 3H-thymidine
labelling index (McDiwitt et al., 1986) as well as between
SPF and expression of proliferation antigens (Dawson et al.,
1990).
Our results indicate that determination of tumour cell
proliferation by flow cytometric SPF analysis reflects the
inherent biological aggressiveness and therapy responsiveness
of prostatic carcinomas. Analysis of tumour proliferation
rate may in the near future play a major role in improving
prognostic and therapeutic assessments of patients. Although
the subgroups that most likely would benefit from the
analysis are not yet known, determination of tumour pro-
liferation rate should be incorporated into randomised
clinical trials on prostate cancer therapy.
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